Equities

Beijing Kawin Technology Share-Holding Co Ltd

688687:SHH

Beijing Kawin Technology Share-Holding Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)28.76
  • Today's Change-0.48 / -1.64%
  • Shares traded4.99m
  • 1 Year change-2.77%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy5
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in CNY

The 2 analysts offering 12 month price targets for Beijing Kawin Technol Sha-hld Co Ltd have a median target of 37.82, with a high estimate of 44.13 and a low estimate of 31.51. The median estimate represents a 31.50% increase from the last price of 28.76.
High53.4%44.13
Med31.5%37.82
Low9.6%31.51

Dividends

In 2023, Beijing Kawin Technology Share-Holding Co Ltd reported a dividend of 0.25 CNY, which represents a 25.00% increase over last year. The 3 analysts covering the company expect dividends of 0.26 CNY for the upcoming fiscal year, an increase of 4.00%.
Div growth (TTM)25.00%
More ▼

Earnings history & estimates in CNY

Beijing Kawin Technol Sha-hld Co Ltd reported annual 2023 earnings of 0.693 per share on Feb 23, 2024.
Average growth rate+41.43%
More ▼

Revenue history & estimates in CNY

Beijing Kawin Technol Sha-hld Co Ltd had revenues for the full year 2023 of 1.41bn. This was 21.74% above the prior year's results.
Average growth rate+21.74%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.